4163-84-2

Upstream product

• 23886-64-8 2,5-dibromobenzenesulfonyl chloride 
• 74-88-4 methyl iodide 
• 4143-36-6 Monothiophosphorsaeure-O,O-dimethylester-S-<2,5-dibrom-phenylester> 

Downstream Products

• 118412-88-7 C₉H₆N₂O₂S 
• 1431501-18-6 N,N-dibutyl-3-(methylsulfonyl)-2-phenoxy-5-(1H-tetrazol-5-yl)aniline 
• 1431504-21-0 3-(dibutylamino)-5-(methylsulfonyl)-4-phenoxybenzonitrile 
• 1431501-19-7 N,N-dibutyl-5-(1H-imidazol-1-yl)-3-(methylsulfonyl)-2-phenoxyaniline 
• 1431501-20-0 N,N-dibutyl-5-(1H-imidazol-2-yl)-3-(methylsulfonyl)-2-phenoxyaniline 
• 1431504-25-4 5-bromo-N,N-dibutyl-3-(methylsulfonyl)-2-phenoxyaniline 
• 1431504-26-5 5-bromo-N-butyl-3-(methylsulfonyl)-2-phenoxyaniline 
• 1431501-21-1 N,N-dibutyl-3-(methylsulfonyl)-2-phenoxy-5-(1H-pyrazol-4-yl)aniline 
• 1431501-22-2 N,N-dibutyl-3-(methylsulfonyl)-2-phenoxy-5-(1H-pyrazol-3-yl)aniline 
• 1431501-24-4 3-(3-(dibutylamino)-5-(methylsulfonyl)-4-phenoxyphenyl)-1,2,4-oxadiazol-5(4H)-one 
• 1431501-25-5 N,N-dibutyl-5-(1H-imidazol-5-yl)-3-(methylsulfonyl)-2-phenoxyaniline 
• 1431501-28-8 4-(3-(dibutylamino)-5-(methylsulfonyl)-4-phenoxyphenyl)-3H-1,2,3,5-oxathiadiazole-2-oxide 
• 1431505-32-6 2,5-dibromo-1-(methylsulfonyl)-3-nitrobenzene 
• 1431505-33-7 5-bromo-1-(methylsulfonyl)-3-nitro-2-phenoxybenzene 

Relevant academic research and scientific papers

2,3,5 TRISUBSTITUTED ARYL AND HETEROARYL AMINO DERIVATIVES, COMPOSITIONS, AND METHODS OF USE

Compounds are disclosed that have a formula represented by the following:(I) wherein Cy, L1 R1, R2a, R2b, R3, R4, n, and L2 are as described herein. These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, autism, bipolar disorder, cancer, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma, Huntington's Disease, inflammatory pain, insomnia, ischemia, migraine, migraine with aura, migraine without aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, itch, excessive itch, Pruritis, neuropathic pruritis, Parkinson's disease, personality disorders, postherpetic neuralgia, psychosis, schizophrenia, seizure disorders, tinnitus, and withdrawal syndromes.

Multicyclic bis-amide MMP inhibitors

The present invention relates generally to bis-amide group containing pharmaceutical agents, and in particular, to multicyclic bis-amide MMP-13 inhibitor compounds. More particularly, the present invention provides a new class of MMP-13 inhibiting compounds, containing a pyrimidinyl bis-amide group in combination with a heterocyclic moiety, that exhibit an increased potency and solubility in relation to currently known bis-amide group containing MMP-13 inhibitors.